{"id":159478,"date":"2022-06-30T07:02:55","date_gmt":"2022-06-30T07:02:55","guid":{"rendered":"https:\/\/precoinnews.com\/?p=159478"},"modified":"2022-06-30T07:02:55","modified_gmt":"2022-06-30T07:02:55","slug":"astrazeneca-imfinzi-plus-chemotherapy-improved-pcr-in-resectable-lung-cancer-quick-facts","status":"publish","type":"post","link":"https:\/\/precoinnews.com\/markets\/astrazeneca-imfinzi-plus-chemotherapy-improved-pcr-in-resectable-lung-cancer-quick-facts\/","title":{"rendered":"AstraZeneca: Imfinzi Plus Chemotherapy Improved PCR In Resectable Lung Cancer – Quick Facts"},"content":{"rendered":"
British drug major AstraZeneca Plc. (AZN.L,AZN) Thursday announced positive high-level results from a planned interim analysis of the AEGEAN Phase III trial that evaluated Imfinzi (durvalumab) plus chemotherapy in resectable non-small cell lung cancer.<\/p>\n
The company noted that Imfinzi in combination with neoadjuvant chemotherapy before surgery demonstrated a statistically significant and meaningful improvement in pathologic complete response or pCR compared to neoadjuvant chemotherapy alone for patients with resectable non-small cell lung cancer or NSCLC.<\/p>\n
A statistically significant improvement in major pathologic response or MPR was also observed. <\/p>\n
The trial will continue to assess the additional primary endpoint of event-free survival or EFS to which the company, investigators and participants remain blinded.<\/p>\n
The company said the safety and tolerability of adding Imfinzi to neoadjuvant chemotherapy was consistent with the known profile for this combination.<\/p>\n
AstraZeneca will share the pCR data with global health<\/span> authorities and present at a forthcoming medical meeting when EFS results are available.<\/p>\n Imfinzi is approved in the curative-intent setting of unresectable Stage III NSCLC in patients whose disease has not progressed after chemoradiotherapy in the US, Japan, China, across the EU and many other countries.<\/p>\n Imfinzi is also approved in the US, EU, Japan, China and many other countries around the world for the treatment of extensive-stage SCLC based on the CASPIAN Phase III trial. <\/p>\n